Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma...
15 KB (1,447 words) - 06:28, 15 September 2024
non-small cell lung cancer. Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer. Avelumab is FDA approved for the treatment...
35 KB (3,450 words) - 17:21, 27 September 2024
Cancer immunotherapy (section Avelumab)
was approved for medical use in the United States in September 2024. Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody...
92 KB (12,353 words) - 07:41, 15 September 2024
Human Immunosuppression: Abrilumab Adalimumab# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab...
38 KB (4,316 words) - 10:24, 26 August 2024
small cell lung cancer, hepatocellular carcinoma, metastatic melanoma Avelumab Bavencio Merck KGaA and Pfizer PD-L1 2017 Merkel cell carcinoma, urothelial...
21 KB (2,093 words) - 02:41, 1 September 2024
BMS-936559 (Bristol Myers Squibb). Both atezolizumab (MPDL3280A, Roche) and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) target the similar PD-L1 receptor...
39 KB (5,010 words) - 05:27, 17 August 2024
work has led to the establishment of several novel drugs (cabozantinib, avelumab, pazopanib and others including combinations) and prognostic factors in...
17 KB (1,497 words) - 16:35, 25 November 2023
the U.S. Food and Drug Administration granted accelerated approval to avelumab, a PDL1 inhibitor, to treat adults and children above 12 years with metastatic...
50 KB (5,542 words) - 17:33, 28 September 2024
breast cancer Tafamidis meglumine Foldrx Pharmaceuticals cardiomyopathy Avelumab EMD Serono advanced renal cell carcinoma Venetoclax AbbVie chronic lymphocytic...
34 KB (180 words) - 22:09, 8 April 2024
results in more progression of the cancer than pembrolizumab, axitinib and avelumab. In comparison to pembrolizumab and axitinib, it probably results in more...
101 KB (10,959 words) - 10:41, 18 September 2024
nivolumab, and are inhibitors of programmed cell-death ligand 1 (PD-1). Avelumab, atezolizumab and durvalumab are inhibitors of PD-L1. Pembrolizumab probably...
88 KB (8,969 words) - 20:03, 19 September 2024
trials. Clinically available examples include durvalumab, atezolizumab and avelumab. In normal tissue, feedback between transcription factors like STAT3 and...
25 KB (3,052 words) - 15:34, 14 September 2024
human Rhesus factor hemolytic disease of the newborn[citation needed] Avelumab Bavencio mab human PD-L1 Y cancer Axatilimab Niktimvo mab humanized CSF1R...
136 KB (4,020 words) - 06:13, 27 September 2024
These checkpoint inhibitors include pembrolizumab, nivolumab, ipilimumab, avelumab, atezolizumab, and durvalumab. From a total 5,898 patients who received...
84 KB (8,872 words) - 10:43, 13 September 2024
(Gemtuzumab ozogamicin) Other Amivantamab Atezolizumab (+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab...
12 KB (808 words) - 05:25, 15 September 2024
Urothelial carcinoma Metastatic non-small cell lung cancer 761041 Link avelumab Bavencio EMD Serono 3/23/2017 intravenous fully human PD-L1 Metastatic...
57 KB (4,072 words) - 11:12, 5 August 2024
collaboration with Pfizer to evaluate combination of Bempegaldesleukin with avelumab and talazoparib or enzalutamide in multiple cancers. In March 2022 it was...
7 KB (599 words) - 00:43, 16 August 2023
studied. Dostarlimab exhibits better efficacy than PD-L1 inhibitors, such as avelumab and durvalumab, in dMMR advanced endometrial cancers. Efficacy of the drug...
37 KB (3,213 words) - 06:55, 8 August 2024
Necitumumab L01FF01 Nivolumab L01FF02 Pembrolizumab L01FF03 Durvalumab L01FF04 Avelumab L01FF05 Atezolizumab L01FF06 Cemiplimab L01FF07 Dostarlimab L01FF08 Prolgolimab...
12 KB (877 words) - 15:36, 25 January 2024
Palbociclib (CDK4/6 inhibitor), Fulvestrant (estrogen receptor antagonist), and Avelumab (monoclonal antibody) for the treatment of metastatic ER+ HER- breast cancer...
24 KB (2,633 words) - 00:57, 22 April 2024
with metastatic bladder cancer who are receiving chemotherapy followed by avelumab. Rintodestrant, an oral selective estrogen receptor degrader (SERD), is...
20 KB (2,065 words) - 01:40, 29 December 2023
refractory to PD-L1 or PD-1 therapies such as pembrolizumab, nivolumab, avelumab) Second-line HNSCC In each of the three indications, a first cohort of...
20 KB (2,722 words) - 14:27, 18 September 2024
A.; Uemura, Motohide; Pal, Sumanta K.; Alekseev, Boris (2020-09-07). "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker...
25 KB (2,535 words) - 09:22, 8 April 2023
in a Phase Ib/II clinical trial evaluating TG4001 in combination with avelumab (in collaboration with Merck KGaA and Pfizer) in patients with advanced...
13 KB (1,178 words) - 21:27, 3 September 2024
antibody drugs, e.g. pembrolizumab, atezolizumab, durvalumab nivolumab, and avelumab, bind to and inhibit the stimulation of PD-1 on CD8+ T cells by PD-L1....
11 KB (1,412 words) - 07:13, 25 June 2024
PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. (November 2020). "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker...
13 KB (1,146 words) - 19:53, 6 February 2024
(Gemtuzumab ozogamicin) Other Amivantamab Atezolizumab (+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab...
12 KB (758 words) - 23:46, 14 March 2024
in cancer and genitourinary tumors. She led the bladder cancer study of avelumab that resulted in FDA approval in advanced bladder cancer. Apolo received...
5 KB (449 words) - 05:07, 9 August 2024
cancer, he is developing immune therapy in ovarian cancer and studies avelumab and nivolumab alone or in combination. While discussing COVID-19 and ovarian...
28 KB (3,247 words) - 04:38, 28 July 2024
Human Immunosuppression: Abrilumab Adalimumab# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab...
2 KB (87 words) - 01:28, 30 May 2023